Microsatellite Instability: Clinical Trials

5 trials for Microsatellite Instability, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed. 5 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 15Completed 5
Phase 22Completed 2

Follow Microsatellite Instability: new trials by email Literature Review of Microsatellite Instability trials Research Report on Microsatellite Instability

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
FT500, Nivolumab, Pembrolizumab - Advanced Solid Tumors, Lymphoma
Phase 1CompletedFate Therapeutics372019-02-152023-05-01
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
INCAGN02385 - Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer
Phase 1CompletedIncyte Biosciences International Sàrl222018-06-182020-10-30
M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability
Anti-PD-L1/TGFbetaRII Fusion Protein M7824 - Colon Adenocarcinoma, High-Frequency Microsatellite Instability
Phase 1 / Phase 2CompletedM.D. Anderson Cancer Center42018-03-072024-11-27
APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors
APL-501 - Solid Tumor, Microsatellite Instability
Phase 1CompletedApollomics (Australia) Pty. Ltd.302017-03-272022-05-09
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
MK-3475, INCB024360 - Microsatellite-instability (MSI) High Colorectal Cancer (CRC), Endometrial Cancer
Phase 1 / Phase 2CompletedIncyte Corporation4442014-07-172022-02-14

Narrower conditions

Carcinoma, Hepatocellular (3)  ·  Carcinoma, Renal Cell (3)  ·  Melanoma (3)  ·  Stomach Neoplasms (3)  ·  Carcinoma, Merkel Cell (2)  ·  Carcinoma, Transitional Cell (2)  ·  Colorectal Neoplasms (2)  ·  Head and Neck Neoplasms (2)  ·  Lymphoma (2)  ·  Neoplasm Metastasis (2)  ·  Ovarian Neoplasms (2)  ·  Small Cell Lung Carcinoma (2)  ·  Triple Negative Breast Neoplasms (2)  ·  Uterine Cervical Neoplasms (2)

Broader conditions

Genomic Instability (5)  ·  Neoplasms (5)  ·  Pathologic Processes (5)  ·  Pathological Conditions, Signs and Symptoms (5)  ·  Digestive System Diseases (4)  ·  Digestive System Neoplasms (4)  ·  Gastrointestinal Diseases (4)  ·  Gastrointestinal Neoplasms (4)  ·  Neoplasms by Site (4)  ·  Adenocarcinoma (3)  ·  Breast Diseases (3)  ·  Carcinoma (3)  ·  Endocrine Gland Neoplasms (3)  ·  Endocrine System Diseases (3)  ·  Female Urogenital Diseases (3)

Interventions

pembrolizumab (2)  ·  Cyclophosphamide (1)  ·  Interleukin-2 (1)  ·  Nivolumab (1)  ·  aldesleukin (1)  ·  atezolizumab (1)  ·  bintrafusp alfa protein, human (1)  ·  epacadostat (1)  ·  fludarabine (1)

Sponsors

Apollomics (Australia) Pty. Ltd. (1)  ·  Fate Therapeutics (1)  ·  Incyte Biosciences International Sàrl (1)  ·  Incyte Corporation (1)  ·  M.D. Anderson Cancer Center (1)

Countries

United States (4)  ·  Australia (1)

Top investigators

John Janik, MD (1)  ·  Marietta Franco (1)  ·  Mark Jones, MD (1)  ·  Van K Morris, MD (1)

Results publications

PMID 33109741